8-K: Spruce Biosciences Secures $50M Growth Capital

Spruce Biosciences has secured up to $50 million in growth capital from Avenue Capital, extending its cash runway into 2027 to advance its lead therapy for Sanfillipo Syndrome Type B.

Summary

• Spruce Biosciences, Inc. entered into a Loan and Security Agreement with Avenue Capital Management II, L.P. and Avenue Venture Opportunities Fund II, L.P. for up to $50.0 million in term loans.
• The loan facility is structured in four tranches: $15.0 million (Tranche 1) funded within 5 business days of January 7, 2026; up to $10.0 million (Tranche 2) available between March 1, 2026, and September 30, 2026, subject to a key regulatory milestone for tralesinidase alfa enzyme replacement therapy (TA-ERT) for Sanfillipo Syndrome Type B (MPS IIIB); up to $15.0 million (Tranche 3) available between September 1, 2026, and March 31, 2027, subject to an additional key regulatory milestone for TA-ERT; and a discretionary Tranche 4 of up to $10.0 million available between October 1, 2027, and June 30, 2028, subject to a commercial milestone and mutual agreement.
• The loans bear interest at an annual rate equal to the greater of (x) 5.25% plus the prime rate as reported in The Wall Street Journal and (y) 12.25%.
• The loans are secured by a lien upon and security interest in all of the company's assets, including intellectual property, subject to agreed exceptions.
• The maturity date for the loans is July 1, 2029, with an initial 12-month interest-only period, extendable by 6 months (Tranche 2 funding) and an additional 12 months (Tranche 3 milestone), up to a maximum of 30 months.
• Prepayment fees apply: 3.0% (within 1 year), 2.0% (1-2 years), and 1.0% (after 2 years). A final payment of 4.00% of the aggregate commitment ($40.0 million or $50.0 million if Tranche 4 is funded) is also due.
• The company paid a commitment fee of $400,000 to the Lender.
• The Lender has a Conversion Option to convert up to $4.0 million of outstanding principal into common stock at 120% of the Warrant exercise price, upon the filing of the company's annual report on Form 10-K for the fiscal year ending December 31, 2025.
• A warrant will be issued to the Lender to purchase up to $3,200,000 worth of common stock, expiring January 31, 2031, with an exercise price equal to the lesser of $84.75 and the price per share of the company's next bona fide equity financing before June 30, 2026.
• In connection with a change of control, the Lender is entitled to the shares underlying the warrant without payment or a $6,400,000 success fee if the change of control occurs before warrant issuance.
• The company's preliminary unaudited cash and cash equivalents were approximately $48.9 million as of December 31, 2025.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive. While securing significant funding and extending the cash runway is a strong positive for a biotech company, the terms of the debt, including high interest rates, substantial fees, and potential equity dilution through warrants and conversion options, suggest a high cost of capital and inherent risks associated with the company's stage of development and financial position.

Positives

• The initial $15.0 million funding from Tranche 1 is expected to extend the company's cash and cash equivalents runway into 2027.
• The financing provides capital to support the biologics license application (BLA) filing of TA-ERT for MPS IIIB and accelerate pre-launch commercial activities.
• TA-ERT has the potential to be the first disease-modifying therapy to treat MPS IIIB, addressing a significant unmet medical need with no current FDA-approved treatments.
• The loan agreement does not contain any minimum cash requirement or other financial covenants, offering some operational flexibility.

Negatives

• The interest rate on the loans is high, at the greater of 5.25% plus the prime rate or 12.25% annually.
• The loans are secured by a lien on all of the company's assets, including intellectual property, which is a significant encumbrance.
• The company is subject to various fees, including a $400,000 commitment fee, prepayment fees (up to 3.0%), and a final payment of 4.00% of the total commitment.
• The Conversion Option and Warrant introduce potential dilution for existing shareholders, with the Lender having the right to convert up to $4.0 million of principal and purchase $3.2 million worth of common stock.
• Future tranches of the loan are contingent on achieving key regulatory and commercial milestones, which introduces uncertainty regarding the full $50.0 million availability.

Risks

• Achievement of key regulatory milestones for TA-ERT for MPS IIIB is required for the funding of Tranche 2 and Tranche 3, and a commercial milestone for Discretionary Tranche 4.
• The preliminary unaudited cash and cash equivalents as of December 31, 2025, are subject to change upon completion of the company's financial statement closing procedures.
• Actual results and performance could differ materially from forward-looking statements due to market conditions and uncertainties related to the offering.
• The company's business is subject to various risks and uncertainties, including geopolitical and macroeconomic events, as detailed in its SEC filings.
• An ongoing UK/UPC case regarding Patent EP 3 784 233 initiated by Neurocrine poses a legal risk.

Future Outlook

The company expects the initial $15.0 million tranche to fund planned operations into 2027. This capital will support the biologics license application (BLA) filing of TA-ERT for the treatment of MPS IIIB and accelerate pre-launch commercial activities. Management believes TA-ERT has the potential to be the first disease-modifying therapy for MPS IIIB.

Management Comments

• Samir Gharib, President and Chief Financial Officer of Spruce Biosciences, stated: 'We are pleased to partner with Avenue Capital on a strategic financing agreement with attractive terms that strengthens our financial flexibility. At the drawdown of the initial $15 million tranche, we expect our cash and cash equivalents to fund planned operations into 2027, supporting the biologics license application (BLA) filing of TA-ERT for the treatment of MPS IIIB, while also accelerating pre-launch commercial activities.'
• Chad Norman, Senior Portfolio Manager at Avenue Capital, commented: 'We believe Spruce is well-positioned to advance and potentially launch TA-ERT as the first disease-modifying therapy to treat MPS IIIB, and were proud to be partnering with this outstanding team to advance that mission. With no FDA-approved treatments currently available to treat MPS IIIB, TA-ERT has the potential to be a groundbreaking advancement for patients and families impacted by this devastating disease.'

Industry Context

This financing positions Spruce Biosciences to continue development and potential commercialization of TA-ERT for Sanfillipo Syndrome Type B (MPS IIIB), a neurological disorder with a significant unmet medical need. The absence of any FDA-approved treatments for MPS IIIB highlights TA-ERT's potential to be a first-in-class, disease-modifying therapy, which could be a significant advancement for patients and a substantial market opportunity for Spruce Biosciences within the rare disease space.

Legal Proceedings

• An ongoing UK/UPC case regarding Patent EP 3 784 233 initiated by Neurocrine is pending.

Stakeholder Impact

• Shareholders: Potential for dilution from the warrant and conversion option, but also benefit from extended cash runway and continued development of TA-ERT.
• Patients with MPS IIIB: Continued development of TA-ERT offers hope for a potential first disease-modifying therapy.
• Employees: The financing supports continued operations and advancement of the lead program.
• Creditors (Avenue Capital): Becomes a secured creditor with a lien on all company assets and potential for equity upside.

Next Steps

• Complete the biologics license application (BLA) filing of TA-ERT for the treatment of MPS IIIB.
• Accelerate pre-launch commercial activities for TA-ERT.
• Achieve key regulatory milestones for TA-ERT to unlock Tranche 2 and Tranche 3 funding.
• Achieve a commercial milestone for TA-ERT and obtain mutual agreement/Lender's investment committee approval for Discretionary Tranche 4 funding.
• File the annual report on Form 10-K for the fiscal year ending December 31, 2025, which will trigger the issuance of the Warrant and the availability of the Conversion Option.

Key Dates

Recommendation

The securing of up to $50 million in growth capital is a crucial development for Spruce Biosciences, extending its cash runway and enabling continued progress on its lead program, TA-ERT, for a high unmet medical need. This provides stability and a clear path for the BLA filing and pre-launch activities. However, the terms of the financing are quite expensive, featuring a high interest rate, significant fees, and potential equity dilution through warrants and a conversion option. These costs reflect the inherent risks in biopharmaceutical development and the company's current financial position. For a seasoned investor, the positive of extended runway and program advancement is balanced by the dilutive and costly nature of the financing, suggesting a 'hold' recommendation as the company navigates these next critical milestones.

Keywords

Spruce Biosciences, SPRB, Avenue Capital, Growth Capital, Loan Agreement, Debt Financing, Biopharmaceutical, Neurological Disorders, Sanfillipo Syndrome Type B, MPS IIIB, Tralesinidase Alfa Enzyme Replacement Therapy, TA-ERT, BLA Filing, Cash Runway, Warrant, Conversion Option, SEC Filing, 8-K